

## BIOTECH CLUB BULLETIN

-----  
June 17, 2005  
-----

BOSTON'S BIOTECH BULLETIN is distributed electronically once a week and contains biotech-related news and announcements of interest to students, faculty, and business professionals.

BOSTON'S BIOTECH BULLETIN is a free service provided by the GSAS HARVARD BIOTECHNOLOGY CLUB. Visit the website at [www.TheBiotechClub.org](http://www.TheBiotechClub.org) for more information about the Biotech Club and to become a member and subscribe to the email list. Links to maps of local campuses are also available on the Events Page.

If are holding events that are free and open to the public, you may submit them to BOSTON'S BIOTECH BULLETIN at our Event Submission page:

[http://www.thebiotechclub.org/events/submit\\_login.php?url=submit.php](http://www.thebiotechclub.org/events/submit_login.php?url=submit.php)

## ----- CLUB EVENTS -----

### 1. HARVARD BIOTECHNOLOGY CLUB ANNOUNCES THE WINNERS OF THE 2005 BIOTECHNOLOGY BUSINESS PLAN COMPETITION - June 17, 2005 -----

### 1. HARVARD BIOTECHNOLOGY CLUB ANNOUNCES THE WINNERS OF THE 2005 BIOTECHNOLOGY BUSINESS PLAN COMPETITION

DATE: June 17, 2005

TIME: 9 AM

CONTACT EMAIL: [patrick@thebiotechclub.org](mailto:patrick@thebiotechclub.org)

LOCATION: N/A, N/A, Boston, Massachusetts

Boston, June 10 2005 -- In the 2005 Biotechnology Business Plan Competition organized by the GSAS Harvard Biotechnology Club, Claros and Vascular Precision were awarded the top prizes by a panel of judges composed of leading venture capital firms.

At the award ceremony was hosted by Brown Rudnick Berlack Israels LLP Claros was awarded the first prize in the competition. The judges clearly favored Claros in the competition stating that they possess the combination of a solid team and a clear solution to complex problem with a large market. Claros has designed an easy-to-use device that performs complex immunoassays with minimal time and resources. The company has chosen the STD market to launch the device where it is primed for rapid adoption in the home market due to privacy issues with STD testing. Thekla Diehl, the director of the competition said that with their management team and novel device it was clearly a winner for this competition. Claros walked

away with a legal package from Brown Rudnick, \$25,000 credit towards leasing lab space with Cummings Properties and a \$5000 cash prize.

The second place prize was awarded to Vascular Precision who have developed a novel vascular closure device for large arteriotomy sites that meets a well-defined market with unmet needs. Vascular Precision's products enable surgeons to close both large and small arteriotomies percutaneously and achieve complete hemostasis along the entire arteriotomy profile, regardless of its size. Vascular Precision was also awarded a legal package from Brown Rudnick as well as a \$1000 cash prize.

Judges in the competition included representatives from the following venture firms: Flagship Ventures, Oxford Bioscience Partners, CPP Capital, Versant Ventures, Seaflounder Ventures, Venrock and PureTech Ventures. The prizes and competition were made possible through the continued support of Brown Rudnick Berlack Israels LLP, Cummings Properties and Merck Research Laboratories-Boston.

The GSAS Harvard Technology Club is a non-profit organization with over 5,000 members in both industry and academia. Among other activities, the club hosts events and provides services that allow members to explore the worlds of business and biotechnology. The Club's mission is to bridge the gap between industry and academia by building relationships with companies operating in the biotechnology and healthcare sphere. Corporate sponsorship support all club activities and operations.

To learn out more about the 2005 Biotechnology Business Plan Competition or the GSAS Harvard Biotechnology Club please contact Patrick Loerch, Managing Director (617) 938-6228 – [patrick@thebiotechclub.org](mailto:patrick@thebiotechclub.org) or visit [www.thebiotechclub.org](http://www.thebiotechclub.org).

---

#### MEMBER EVENTS

---

1. SINO-AMERICAN PHARMACEUTICAL PROFESSIONALS ASSOCIATION-NEW ENGLAND(SAPA-NE) 8TH ANNUAL CONFERENCE - June 18, 2005
  2. BIOMAVENS: A BIOTECH/MEDICAL DEVICE NETWORKING EVENT - June 30, 2005
- 

#### 1. SINO-AMERICAN PHARMACEUTICAL PROFESSIONALS ASSOCIATION-NEW ENGLAND(SAPA-NE) 8TH ANNUAL CONFERENCE

DATE: June 18, 2005  
TIME: a day AM  
CONTACT EMAIL: [Erxi.Wu@childrens.harvard.edu](mailto:Erxi.Wu@childrens.harvard.edu)

Sino-American Pharmaceutical Professionals Association-  
New England(SAPA-NE)

([www.sapa-ne.org](http://www.sapa-ne.org))

SAPA-NE 8th Annual Conference

Advancing Drug Discovery & Development

Saturday June 18, 2005

Wong Auditorium  
Tang Center, Building E51  
Sloan School of Management

Massachusetts Institute of Technology (MIT)  
Cambridge, MA 02139

7:50 – 8:50           Registration\* and Breakfast

Opening Remarks

8:50 – 9:00           Harry Huimin Chen, Ph.D.  
SAPA-NE 8th Annual Conference Chair, SAPA-NE President-elect

Session 1: Strategic Planning and Monitoring in R&D

9:00– 9:40  
Steven J. Projan, Ph.D.  
Vice President, Biological Technologies, Wyeth Research

"Targeted Chemotherapy: A One Hit Wonder?"

9:40– 10:20  
Klaus Melchers, Ph.D.  
Vice President & Chief Operating Officer, ALTANA Research Institute.  
"Application of an Integrated Biological and Chemical Genomics Platform for Drug Profiling and the Identification and Validation of Drug Targets"

10:20 – 10:50       Coffee Break and Exhibition

Session 2: Emerging Technologies in R&D

10:50– 11:30  
Michael Melnick, Ph.D.  
Vice President, Business and Corporate Development, Cell Signaling Technology

"Phospho-Proteomics of Cancer"?"

11:30– 12:10  
Shi-Chung Ng, Ph.D.  
Vice President, and Head of Chemical Genomics, ArQule, Inc.  
"Drug Discovery by Chemical Genomics"

12:10 – 1:30       Lunch and Exhibition

1:30 – 2:10  
Alexander Kamb, Ph.D.  
Vice President, Global Head Oncology, Novartis Institutes for Biomedical Research (NIBR)

Title: "What is wrong with our cancer models

Session 3: New Opportunity in China

2:10 – 2:50  
Brian Seed, Ph.D.  
Professor of Genetics, Harvard Medical School

"Preliminary Experience with a Chinese-American Drug Development Program"

2:50 – 3:20

Coffee Break and Exhibition

3:20 – 4:00

Qian Liu, Professor

Vice Dean, Chinese Academy of Medical Sciences & Peking Union Medical College

"Present State of Basic Research and Drug Development in China"

4:00– 5:00

TBA

Chinese Pharmaceutical Delegations

"TBA"

6:00– 8:00

Cocktail Reception

Place: MIT faculty club or Marriott at Kendal Square

Activity:

1. SAPA-NE Award Presentation;
2. Brief speeches from Chinese Pharmaceutical Delegations;
3. Networking opportunity among speakers, sponsors, vendors and attendees.

Drinks and a gourmet Italian buffet will be served.

Ticket is required for Reception\*\*

Who should attend?

- Professionals in pharmaceutical and medical science.
- Professionals in new technology development, global business development and licensing, alliance management, corporate strategy and business development of drug discovery and development.

Sponsorship Opportunity is Available!

Endorse Bio-pharmaceutical research and development, promote science and technology exchange between America and China, support Chinese community, showcase your company's expertise, introduce your products, recruit top scientist, by becoming a sponsor of SAPA-NE 8th Annual Symposium. Please contact [conference@sapa-ne.org](mailto:conference@sapa-ne.org) for detail.

Vender Show is Available!

Showcase your company's expertise, introduce your products, recruit top scientist, by becoming an exhibitor of SAPA-NE 8th Annual Symposium. Please contact [suema001@aol.com](mailto:suema001@aol.com) for detail.

Contact Information

By email: [conference@sapa-ne.org](mailto:conference@sapa-ne.org)

Website: [www.SAPA-NE.org](http://www.SAPA-NE.org)

\* The capacity of the conference is limited to 400 people and the dinner reception is limited to 100 people.

Registration on-site:

Free for SAPA –NE members and employees of corporate sponsors (company ID required)

Membership renewal and application is available on site;  
\$20 Annual Membership fee;  
\$200 Lifetime membership fee;  
\$10 Student and Postdoc, (student ID required)

\$ 30 for general public.

\*\*Ticket is required for Reception:

Free for speakers, sponsors, vendors and invited VIP

\$ 25 for SAPA-NE members and general public.

## 2. BIOMAVENS: A BIOTECH/MEDICAL DEVICE NETWORKING EVENT

DATE: June 30, 2005

TIME: 5:30 PM

CONTACT EMAIL: sharondianne18@yahoo.com

The Biotech Life -Sciences Group is a diverse community of individuals representing the full spectrum of the biotech industry in Boston, including biotechnology and pharmaceutical companies, medical device corporations, venture capital firms and consulting firms in the areas of Research Development, Regulatory Affairs, Clinical Trials, Program Management, Business Development, Patent Law, and Investments. To learn more about our group, including information on this event and how to register for it, please visit: <http://www.cjp.org/biotech>.

---

### NEWS

---

Headline: CHIRON WARNS IT WILL MAKE FEWER FLU SHOTS

Source: Associated Press

Chiron Corp. said it may not deliver as many flu shots this year as it had promised, prompting the beleaguered biotechnology company to cut its 2005 financial forecast.

[http://biz.yahoo.com/ap/050615/chiron\\_flu\\_vaccine.html?.v=13](http://biz.yahoo.com/ap/050615/chiron_flu_vaccine.html?.v=13)

Headline: CORIXA AND GLAXOSMITHKLINE ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIODJ

Source: Press Release

Corixa Corporation and GlaxoSmithKline announced that the waiting period imposed by the Hart-Scott-Rodino Act in connection with proposed acquisition of Corixa by GlaxoSmithKline expired on June 13, 2005.

<http://biz.yahoo.com/bw/050615/155941.html?.v=1>

Headline: MEDTRONIC BOOSTS PORTFOLIO OF IMPLANTABLE PAIN THERAPIES WITH LATEST FDA APPROVAL

Source: Press Release

Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval and U.S. availability of its SynergyPlus+(TM) neurostimulation system for chronic pain.

<http://biz.yahoo.com/bw/050615/155618.html?.v=1>

Headline: ZAPPING CANCER CELLS

Source: Fortune

While more new wonder drugs like Gleevec are still in the pipeline, Proton therapy is a proven fighter in

the war against cancer. Oncologists have long known that substituting proton radiation for the X-rays now used to treat about half of all cancer patients would do less harm to normal tissues and organs and more damage to malignant growths.

<http://www.fortune.com/fortune/imt/0,15704,1071920,00.html?promoid=yahoo>

Headline: J&J'S HEART DRUG GETS A CHECKUP

Source: BusinessWeek Online

Johnson & Johnson is in damage-control mode. On June 13 it announced the recommendations from a panel J&J had convened to evaluate its heart-failure drug Natrecor after questions mounted about the drug's safety.

[http://yahoo.businessweek.com/technology/content/jun2005/tc20050614\\_6719\\_tc024.htm](http://yahoo.businessweek.com/technology/content/jun2005/tc20050614_6719_tc024.htm)

Headline: BRISTOL-MYERS PLANS WAITING PERIOD ON NEW -DRUG ADS

Source: Reuters

Drug maker Bristol-Myers Squibb said it will wait a year after the launch of any new drug before advertising it directly to consumers in order to give doctors and patients time to discuss new therapies.

[http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh61221\\_2005-06-15\\_01-14-23\\_n14220944\\_newsml](http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh61221_2005-06-15_01-14-23_n14220944_newsml)

Headline: ONE DRUG, TWO VIEWS

Source: The Boston Globe

The future of multiple sclerosis drug Tysabri, which drug firms Biogen Idec, Inc. and Elan Corp. collaborate on, appears to change depending on which company you ask.

[http://www.boston.com/business/globe/articles/2005/06/14/one\\_drug\\_two\\_views/](http://www.boston.com/business/globe/articles/2005/06/14/one_drug_two_views/)

Headline: HIGH-STAKES TRIALS AWAIT DEVICE MAKER

Source: Boston Globe

Three trials about to get underway may show whether the aggressive legal strategy of Boston Scientific Corp.'s general counsel, Paul W. Sandman, will be as successful as the company's medical devices.

[http://www.boston.com/business/globe/articles/2005/06/13/high\\_stakes\\_trials\\_await\\_device\\_maker/](http://www.boston.com/business/globe/articles/2005/06/13/high_stakes_trials_await_device_maker/)

Headline: BIOGEN MS DRUG GETS LIFT

Source: Boston Globe

Recent articles in the New England Medical Journal on Biogen Idec.'s drug Tysabri, which has been pulled off shelves after four users developed a rare brain disease, gave the drug a positive boost by stating it may be safely administered if patients are carefully monitored.

[http://www.boston.com/business/technology/biotechnology/articles/2005/06/10/biogen\\_ms\\_drug\\_gets\\_lift\\_from\\_reports/](http://www.boston.com/business/technology/biotechnology/articles/2005/06/10/biogen_ms_drug_gets_lift_from_reports/)

Headline: SURVEYED SCIENTISTS ADMIT MISCONDUCT

Source: Boston Globe

A third of American biomedical scientists have engaged in questionable research practices, according to survey results released that raise questions about the integrity of the nation's multibillion-dollar quest to understand the human body and cure diseases.

[http://www.boston.com/business/technology/biotechnology/articles/2005/06/09/surveyed\\_scientists\\_admit\\_misconduct/](http://www.boston.com/business/technology/biotechnology/articles/2005/06/09/surveyed_scientists_admit_misconduct/)

-----  
Job Postings  
-----

Job Title: RESEARCH ASSOCIATE – GENOMIC SERVICES

Company: Agencourt Bioscience Corp.

Description: Agencourt Bioscience Corporation, located in Beverly, Massachusetts, is a trusted provider of genomic services and nucleic acid purification products. We are dedicated to designing solutions for overcoming all of our clients' current and future discovery challenges. Agencourt is a dynamic and growing company that is committed to providing employees with a fast paced environment and a fun place to

work. As a result of our significant growth, we have an immediate need for a Research Associate – Genomic Services

The Research Associate will be responsible for performing primary R&D on projects that support and develop Agencourt's Genomics Services pipeline. This includes new product/process development to enhance current sequencing technology, SNP detection, expression analysis, and genomic and cDNA library construction.

**Job Title: SENIOR SCIENTIST - PRODUCT DEVELOPMENT**

**Company:** Agencourt Bioscience Corp.

**Description:** Agencourt Bioscience Corporation, located in Beverly, Massachusetts, is a trusted provider of genomic services and nucleic acid purification products. We are dedicated to designing solutions for overcoming all of our clients' current and future discovery challenges. Agencourt is a dynamic and growing company that is committed to providing employees with a fast paced environment and a fun place to work. As a result of our significant growth, we have an immediate need for a Senior Scientist

The Senior Scientist will work as part of a multidisciplinary team responsible for product development in the areas of nucleic acid and protein purification products for genomics and proteomics applications. You will be involved in development of sample preparation, purification and assay chemistry to support development of solid phase based purification kits and reagents for molecular biology.

**Job Title: RESEARCH PROGRAMMER**

**Company:** Agencourt Bioscience Corp.

**Description:** Agencourt Bioscience Corporation, located in Beverly, Massachusetts, is a trusted provider of genomic services and nucleic acid purification products. We are dedicated to designing solutions for overcoming all of our clients' current and future discovery challenges. Agencourt is a dynamic and growing company that is committed to providing employees with a fast paced environment and a fun place to work. As a result of our significant growth, we have an immediate need for a Research Programmer

The role of Programmer will be to support an in-house R&D effort to develop a new DNA sequencing technology.

We seek a productive programmer who enjoys working in an academic style collaborative environment and meets the requirements listed below.

**Job Title: AUTOMATION ENGINEER**

**Company:** Agencourt Bioscience Corp.

**Description:** Agencourt Bioscience Corporation, located in Beverly, Massachusetts, is a trusted provider of genomic services and nucleic acid purification products. We are dedicated to designing solutions for overcoming all of our clients' current and future discovery challenges. Agencourt is a dynamic and growing company that is committed to providing employees with a fast paced environment and a fun place to work. As a result of our significant growth, we have an immediate need for an Automation Engineer.

The Automation Engineer will implement various Genomic sequencing technologies included but not limited to SPRI DNA purification technology on various robotic platforms.

Primary job duties include:

- Write software on various robotic platforms, including PerkinElmer PlateTrak, Beckman Biomek FX/NX, Beckman 3K, PerkinElmer MultiProbe, Tecan Genesis, and Caliper/Zymark systems
- Assist with development of new protocols from an automation viewpoint; use skills in Visual Basic, C and/or C++ to develop software tools for QA/QC of pipeline and integration with Oracle 11i-based LIMS; support technical staff in technical aspects of daily operation
- Manage engineering efforts to enhance robotics performance and reliability

- Work with systems manufacturers to improve instrument throughput, usability and suitability
- Work with sales team and customers to implement SPRI protocols on client equipment
- Conduct user training and coordinate technical support

---

## SPONSORS

---

### Platinum:

Brown Rudnick Berlack Israels LLP, Novartis Institutes for BioMedical Research

### Gold:

Abbott Laboratories, Flagship Ventures, Merck Research Labs, MPM Capital, Nixon Peabody LLP, ParAllele Biosciences, Techno Venture Management, Testa, Hurwitz & Thibault, LLP, Science Careers, Merrimack Pharmaceuticals

---

---

## USEFUL CLUB LINKS

---

### 1. IF YOU LOSE YOUR PASSWORD:

[http://www.thebiotechclub.org/left\\_nav/lostpassword.php](http://www.thebiotechclub.org/left_nav/lostpassword.php)

Enter the email address you receive this bulletin at and your password will be emailed to you.

### 2. EDIT YOUR MEMBERSHIP DATA:

[http://www.thebiotechclub.org/left\\_nav/login.php?purl=edit.php](http://www.thebiotechclub.org/left_nav/login.php?purl=edit.php)

Your login/user name is the email address you receive this bulletin at. The default password is "changeme". You should immediately change this to something of your choosing.

### 3. VIEW JOBS POSTED:

<http://www.thebiotechclub.org/career/index.php>

### 4. POST/EDIT/REMOVE YOUR RESUME:

[http://www.thebiotechclub.org/resume/resume\\_login.php?purl=resume\\_edit.php](http://www.thebiotechclub.org/resume/resume_login.php?purl=resume_edit.php)

### 5. TO UNSUBSCRIBE:

[http://www.thebiotechclub.org/left\\_nav/login.php?purl=remove\\_member.php](http://www.thebiotechclub.org/left_nav/login.php?purl=remove_member.php)

Login and choose unsubscribe

Regards,

Patrick Loerch  
Managing Director